[Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia]

Antibiot Khimioter. 1992 Jul;37(7):47-9.
[Article in Russian]

Abstract

The clinical efficacy of aclarubicin, an anthracycline antibiotic, was studied in 48 patients with leukemia. The antibiotic was used in the following combinations with cytarabine: "7 + 7", "5 + 5" and "7 & 3". A complete remission was stated in 14 (42.4 per cent) out of 33 patients with acute nonlymphoid leukemia, 6 (43 per cent) out of the 14 patients having relapses. The combined therapy was effective in 4 out of 5 pre-resistant patients. The "7 + 3" scheme was the most beneficial. The most common adverse reactions were nausea and vomiting.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Aclarubicin / administration & dosage*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blast Crisis / drug therapy*
  • Cytarabine / administration & dosage*
  • Humans
  • Leukemia / drug therapy*
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Remission Induction

Substances

  • Cytarabine
  • Aclarubicin